Rapport Therapeutics Inc
NASDAQ:RAPP

Watchlist Manager
Rapport Therapeutics Inc Logo
Rapport Therapeutics Inc
NASDAQ:RAPP
Watchlist
Price: 27 USD -6.77%
Market Cap: 1.3B USD

Relative Value

There is not enough data to reliably calculate the relative value of RAPP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RAPP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
-9
Median 5Y
-9
Industry
21.6
Forward
-9.4
vs History
vs Industry
Median 3Y
-11.5
Median 5Y
-11.5
Industry
16.9
vs History
vs Industry
Median 3Y
-10.9
Median 5Y
-10.9
Industry
22.9
vs History
33
vs Industry
Median 3Y
2.3
Median 5Y
2.3
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-5.4
Industry
13.4
Forward
-6.5
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-5.4
Industry
16.7
Forward
-6.4
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-7.1
Industry
16.1
vs History
vs Industry
Median 3Y
-6.7
Median 5Y
-6.7
Industry
18.9
vs History
52
vs Industry
Median 3Y
44.5
Median 5Y
44.5
Industry
2

Multiples Across Competitors

RAPP Competitors Multiples
Rapport Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Rapport Therapeutics Inc
NASDAQ:RAPP
1.3B USD 0 -13.2 -7.1 -7
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
504.1B USD 5.5 20.2 16.4 21.3
CH
Roche Holding AG
SIX:ROG
269.2B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
215.1B GBP 5 30.8 109.1 159.7
CH
Novartis AG
SIX:NOVN
216.4B CHF 4.8 18.9 11.9 15.4
US
Merck & Co Inc
NYSE:MRK
269.1B USD 4.2 14.1 10 11.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.5 13.3
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
142.6B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average P/E: 24.8
Negative Multiple: -13.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.2
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.8
37%
0.8
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average EV/EBITDA: 440.1
Negative Multiple: -7.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109.1
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average EV/EBIT: 1 883.7
Negative Multiple: -7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.4
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4